{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:14:51Z","timestamp":1793495691734,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"\n Background:<\/jats:title>\n Once weekly Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) have been shown to improve glycemic outcomes and cause significant weight loss. However, 9% to 27% of individuals have little or no response to these drugs. In this article, we investigated the efficacy of GLP-1 RA therapy among adults with type 1 diabetes and obesity likely related to genetic mutations compared with obesity likely unrelated to genetic mutations.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n In this retrospective study, we compared body weight and glycated hemoglobin (HbA1c) change with the use of GLP-1 RA therapy (including a dual agonist, Tirzepatide) over six months among adults with type 1 diabetes and obesity likely (n = 11, median age 39.5 years with a median BMI of 43.0 kg\/m\n 2<\/jats:sup>\n ) versus unlikely related to genetic mutation(s) (n = 15, median age 45.8 years with a median BMI of 38.7 kg\/m\n 2<\/jats:sup>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Six months of GLP-1 RA treatment resulted in a numerically lower reduction of weight (\u22125.75 \u00b1 9.46 kg vs \u22128.65 \u00b1 9.36 kg,\n P<\/jats:italic>\n = .44) and HbA1c (\u22120.28 \u00b1 0.96% vs \u22120.43 \u00b1 0.57%,\n P<\/jats:italic>\n = .64) among individuals with obesity likely versus unlikely related to a genetic mutation(s), respectively. Fewer individuals with genetic obesity met goal weight loss \u22655% or HbA1c decrease \u22650.4% than did individuals with obesity unlikely related to a genetic cause (36.4% vs 80.0%,\n P<\/jats:italic>\n = .04).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The weight loss and glycemic lowering effects of GLP-1 RA therapy may be decreased in people with type 1 diabetes and obesity likely related to genetic causes. Further research is needed to understand GLP-1 RA mechanisms via energy regulating genes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/19322968241245680","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:11:35Z","timestamp":1713345095000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5279-3447","authenticated-orcid":false,"given":"Matthew P.","family":"Klein","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-5179","authenticated-orcid":false,"given":"Halis Kaan","family":"Akturk","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-3740","authenticated-orcid":false,"given":"Janet K.","family":"Snell-Bergeon","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-7107","authenticated-orcid":false,"given":"Viral N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3078."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1991"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/endocrines4010008"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac618"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968231223991"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01351-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1170181"},{"key":"e_1_3_3_12_2","unstructured":"Uncovering Rare Obesity: Rhythm Pharmaceuticals Inc. 2023 https:\/\/uncoveringrareobesity.com\/."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0486."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0495."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/db22-719-P."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.05.008"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12546."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0414."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00783-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab905."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417."}],"updated-by":[{"DOI":"10.1177\/19322968241256557","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000}}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968241245680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19322968241245680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968241245680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:16:58Z","timestamp":1777400218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19322968241245680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/19322968241245680"],"URL":"https:\/\/doi.org\/10.1177\/19322968241245680","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}